TLR2 and neoplasm: In lung cancer, silencing TLR2, TLR4, and TLR9, along with epithelial-specific MyD88/NF-κB signaling, significantly reduces the expression of pro-tumor immunosuppressive factors like RETNLB, while enhancing the expression of anti-tumor cytokines like IFN-γ (100).